Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 6/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ADH5 | P11766 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563977 | 0.89 | HSD11B1 (0.45) | HSD11B1KMT2AEGLN2MAPKAPK2MEN1 | |
| SCHEMBL6499258 | 0.84 | MAPKAPK2 (0.47) | HSD11B1MAPKAPK2CNR1CNR2 | |
| SCHEMBL5173712 | 0.78 | HSD11B1 (0.45) | HSD11B1KMT2AEGLN2MEN1TNKS | |
| SCHEMBL5319319 | 0.78 | MAPKAPK2 (0.60) | KMT2AMAPKAPK2MEN1 | |
| SCHEMBL6504779 | 0.76 | MAPKAPK2 (0.46) | HSD11B1KMT2AMAPKAPK2MEN1CNR1 | |
| SCHEMBL27657223 | 0.75 | MAPKAPK2 (0.45) | KMT2AMAPKAPK2MEN1 | |
| SCHEMBL28302004 | 0.73 | MAPKAPK2 (0.53) | KMT2AMAPKAPK2MEN1 | |
| SCHEMBL5751866 | 0.73 | FGFR1 (0.42) | KMT2AMAPKAPK2MEN1 | |
| SCHEMBL27729355 | 0.72 | MAPKAPK2 (0.55) | MAPKAPK2 | |
| SCHEMBL5756138 | 0.72 | TMPRSS4 (0.45) | KMT2AMAPKAPK2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | HSD11B1 1022/4885KMT2A 481/4885EGLN2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.